EGTX Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Egetis Therapeutics (STO: EGTX)
›
Egetis Therapeutics (STO: EGTX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 61 employees.
The shares were at 11.12 SEK on 19 November 2026, up 79.9% over 52 weeks. Its 52-week range is 3.625 SEK to 11.20 SEK, and it trades at the top of that range.
Its market capitalisation is 5.17B SEK.
Egetis Therapeutics reports return on equity of -101.2% and revenue up 23.0% year over year.
It holds more cash than debt, a net cash position of 192.60M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Hold; their mean price target of 11.21 SEK is 0.8% above the current price. The next earnings report is expected on 25 February 2027.